Brii Biosciences Limited
Brii Biosciences Limited (BRIBF) Financial Performance & Income Statement Overview
Analyze Brii Biosciences Limited (BRIBF) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Brii Biosciences Limited (BRIBF) Income Statement & Financial Overview
Analyze Brii Biosciences Limited’s BRIBF earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $32.13M | $22.16M | $8.11M | $8.11M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $32.13M | $22.16M | $8.11M | $8.11M |
| Gross Profit Ratio | $1.00 | $1.00 | $1.00 | $1.00 |
| R&D Expenses | $123.68M | $126.17M | $100.27M | $100.27M |
| SG&A Expenses | $92.36M | $111.58M | $46.86M | $46.86M |
| Operating Expenses | $216.04M | $237.75M | $147.12M | $32.58M |
| Total Costs & Expenses | $216.04M | $237.75M | $147.12M | $32.58M |
| Interest Income | $0.00 | $0.00 | $30.70M | $30.70M |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $4.67M | $2.32M | $1.41M | $1.41M |
| EBITDA | -$179.24M | -$213.28M | -$137.60M | -$137.60M |
| EBITDA Ratio | -$5.58 | -$9.63 | -$16.96 | -$16.96 |
| Operating Income | -$183.91M | -$215.60M | -$139.01M | -$139.01M |
| Operating Income Ratio | -$5.72 | -$9.73 | -$17.14 | -$17.14 |
| Other Income/Expenses (Net) | -$45.24M | -$67.64M | $145.24M | $145.24M |
| Income Before Tax | -$229.14M | -$283.24M | $6.23M | $6.23M |
| Income Before Tax Ratio | -$7.13 | -$12.78 | $0.77 | $0.77 |
| Income Tax Expense | $0.00 | $0.00 | -$1.32M | -$1.32M |
| Net Income | -$227.63M | -$280.54M | $7.54M | $7.54M |
| Net Income Ratio | -$7.08 | -$12.66 | $0.93 | $0.93 |
| EPS | -$0.31 | -$0.38 | $0.01 | $0.01 |
| Diluted EPS | -$0.31 | -$0.38 | $0.01 | $0.01 |
| Weighted Avg Shares Outstanding | $730.78M | $729.72M | $728.75M | $728.75M |
| Weighted Avg Shares Outstanding (Diluted) | $730.78M | $729.71M | $728.71M | $728.71M |
The company's financials show resilient growth, with revenue advancing from $8.11M in Q3 2023 to $32.13M in Q4 2024. Gross profit remained healthy with margins at 100% in Q4 2024 compared to 100% in Q3 2023. Operating income hit -$183.91M last quarter, sustaining a consistent -572% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$179.24M. Net income rose to -$227.63M, while earnings per share reached -$0.31. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan